CV. A Randomized Trial of Icosapent Ethyl in Ambulatory Patients with COVID-19
Andrew Kosmopoulos, et al. https://doi.org/10.1016/j.isci.2021.103040. (https://www.sciencedirect.com/science/article/pii/S2589004221010087) Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 30/08/2021 Highlights hs-CRP was significantly reduced within the icosapent ethyl cohort (P-value=0.011) Treated participants had significant FLU-PRO score reductions versus usual care First evidence of a well-tolerated icosapent ethyl loading dose (8g/day for
CV. A Randomized Trial of Icosapent Ethyl in Ambulatory Patients with COVID-19 Leer más »
